These structures and extensive functional studies reveal high structural flexibility of VMAT2 underlying monoamine storage and demonstrate amphetamine-induced monoamine release, providing a framework for developing targeted therapeutics for neurological disorders and substance abuse. This evidence concerns the gene SLC18A2 and nervous system disorder.